GlassScriptPhysician profile
Erica Person
NPI 1730104902
$3,772.66
in general payments reported to CMS, 2019-2025
29 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $408 · 2021: $626 · 2022: $533 · 2023: $285 · 2024: $536 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,367.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $477.33 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Kala Pharmaceuticals, INC. | $474.36 | 2019-2021 | |
| Abbvie INC. | $300.85 | 2022-2025 | |
| Allergan, INC. | $287.22 | 2019-2022 | |
| Alcon Vision LLC | $239.98 | 2019-2025 | Hydrus Microstent, Rocklatan, Clareon |
| Sight Sciences, INC. | $183.48 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Ivantis, INC | $181.24 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $172.91 | 2020-2023 | |
| Mallinckrodt Enterprises LLC | $145.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $138.27 | 2022-2024 | Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $126.57 | 2019-2025 | |
| Amgen INC. | $122.42 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $116.98 | 2020-2021 | |
| Baxter Healthcare | $103.08 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $97.24 | 2021-2025 | |
| Carl Zeiss Meditec, INC. | $90.04 | 2019-2021 | |
| New World Medical,INC. | $65.88 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $64.68 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $39.24 | 2024 | Xdemvy |
| Ani Pharmaceuticals, INC. | $24.66 | 2024 | Purified Cortrophin Gel |
| Rxsight INC | $22.80 | 2021 | |
| Thea Pharma INC. | $20.52 | 2025 | Iyuzeh |
| Dompe US, INC. | $20.51 | 2021 | |
| Oyster Point Pharma, INC. | $19.73 | 2022 | |
| Horizon Therapeutics Plc | $18.46 | 2023 | Tepezza |
| Biotissue Holdings INC. | $15.46 | 2020 | |
| Apellis Pharmaceuticals, INC. | $15.44 | 2023 | |
| Ocular Therapeutix, INC. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Person listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.